Setmelanotide (Imcivree)
FDA-approved MC4R agonist for genetic obesity disorders — a precision-medicine peptide for patients with specific monogenic conditions.
At a glance
What it is: FDA-approved MC4R agonist for genetic obesity disorders — a precision-medicine peptide for patients with specific monogenic conditions..
Primary research applications:
- POMC, PCSK1, and LEPR deficiency obesity
- Bardet–Biedl syndrome obesity
- Other rare hypothalamic obesity disorders
Editorial summary: Setmelanotide is a striking example of precision-medicine peptide pharmacology. By directly activating MC4R — the brain's master appetite-regulating receptor — it produces meaningful weight loss in patients whose obesity stems from specific upstream genetic defects in the leptin–melanocortin pathway. It is not a general obesity drug, but in the right population the response can be transformative.
- Class / structure
- Synthetic 8-amino-acid cyclic α-MSH analog
- Half-life
- ≈ 11 hours (subcutaneous)
- First described
- 2010s (Rhythm Pharmaceuticals)
- Regulatory status
- FDA-approved (2020 — POMC/PCSK1/LEPR deficiency; 2022 — Bardet–Biedl syndrome)
What is Setmelanotide?
Setmelanotide is a synthetic peptide melanocortin-4 receptor (MC4R) agonist. MC4R is the central node of the brain's leptin–melanocortin appetite-regulation pathway; mutations upstream of it (POMC, PCSK1, LEPR) produce severe early-onset obesity that does not respond to lifestyle interventions or to most other obesity therapeutics.
Discovery and development
Setmelanotide was developed by Rhythm Pharmaceuticals as a selective MC4 receptor agonist with a focused indication strategy: rare genetic obesity disorders where the leptin–melanocortin pathway is disrupted upstream of MC4R. Approval came in 2020 for proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), and leptin receptor (LEPR) deficiency, with expansion to Bardet–Biedl syndrome in 2022.
Mechanism of action
By directly activating MC4R, setmelanotide restores downstream signaling that has been impaired by upstream genetic defects. Patients with intact MC4R but defective upstream pathway components are the ones most likely to respond.[1]
Pharmacokinetics
Once-daily subcutaneous injection. Half-life of approximately 11 hours supports a stable plasma profile across the dosing day.
What the research shows
The peer-reviewed literature on Setmelanotide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Reduces weight in genetic obesity disorders with upstream pathway defects | Phase 3 RCTs | Supported |
| Reduces hyperphagia in these patients | Patient-reported outcome data in trials | Supported |
| Should be used as a general obesity therapy | Approved only for specific rare disorders; broader use not established | Unsupported |
Reported user experiences
How the research describes administration
Once-daily subcutaneous injection. Initiated and managed in centers with experience in genetic obesity disorders, typically following confirmatory genetic testing.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Setmelanotide is one of the cleanest examples of precision-medicine pharmacology in the peptide world. Its narrow but transformative indication for genetic obesity disorders illustrates how matching a targeted therapy to a specific molecular defect can produce outcomes that broader interventions cannot. For the small population it is designed for, it is among the most consequential peptide approvals of the decade.
Frequently asked questions
Why isn't setmelanotide used for general obesity?
It is approved specifically for patients with documented upstream defects in the leptin–melanocortin pathway. In patients without such defects, the pathway is functioning, and direct MC4R agonism does not produce comparable weight loss.
Is setmelanotide related to PT-141 or melanotan-II?
All three are melanocortin receptor agonists with different selectivity profiles. PT-141 is approved for HSDD; melanotan II is unapproved and used for tanning. Setmelanotide is FDA-approved specifically for genetic obesity disorders. The shared mechanism is melanocortin receptor activation; the indications and selectivity differ.
References
- Kühnen P, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240-246. https://pubmed.ncbi.nlm.nih.gov/27468060/
- Clément K, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency. Lancet Diabetes Endocrinol. 2020;8(12):960-970. https://pubmed.ncbi.nlm.nih.gov/33137293/